Dr. Van Veldhuizen on the Combination of Atezolizumab and Bevacizumab in Kidney Cancer
July 13th 2018
Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses the frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the treatment of patients with kidney cancer.